Email this article 
NEW TRENDS IN THE USE OF TAXOTERE (DOCETAXEL) IN PROSTATE CANCER
- Authors: Karyakin O.B.1, Biryukov V.A.1
-
Affiliations:
- Medical Radiology Research Center, Russian Academy of Medical Sciences, Obninsk
- Issue: Vol 5, No 4 (2009)
- Pages: 58-62
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS
- Published: 30.12.2009
- URL: https://oncourology.abvpress.ru/oncur/article/view/302
- DOI: https://doi.org/10.17650/1726-9776-2009-5-4-58-62
- ID: 302
Cite item
Full Text
Abstract
The papers on studies of the efficacy of Taxotere in prostate cancer (PC) are reviewed. The use of Taxotere is shown to increase survival in patients with metastatic hormone-refractory PC. Taxoterebased neoadjuvant and adjuvant chemotherapies are rather safe and have no sig nificant impact on further surgical and radiation therapies in patients with PC.
Keywords
About the authors
O. B. Karyakin
Medical Radiology Research Center, Russian Academy of Medical Sciences, Obninsk
Author for correspondence.
Email: karyakin@mrrc.obninsk.ru
Russian Federation
V. A. Biryukov
Medical Radiology Research Center, Russian Academy of Medical Sciences, Obninsk
Email: karyakin@mrrc.obninsk.ru
Russian Federation
References
Supplementary files
